1. Generics Bulletin
  2. >>Products
  3. >>Generics

Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?

Third Quarter Numbers Follow Sandoz’ View Of ‘Challenging Environment’

 
• By Dean Rudge

Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.

Bumpy road
Are US generics players in for a bumpy road? • Source: Alamy

Teva has followed its rival Sandoz in reporting a soft quarter of US generics sales, adding to debate that recent stability in the US generics sector amid the coronavirus pandemic – stability that Teva itself has repeatedly underlined – is at risk.

The Israeli firm reported North America generics sales, albeit including a small Canadian biosimilars presence, that fell by 7% to $859m in the third quarter. Only 24 hours earlier, Sandoz reported US sales that plunged by a fifth amid price erosion in its base business, acknowledging a “challenging environment” in the market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.